David A. Siegel Kymera Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 336,300 shares of KYMR stock, worth $14.8 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
336,300
Previous 367,000
8.37%
Holding current value
$14.8 Million
Previous $11 Million
45.31%
% of portfolio
0.04%
Previous 0.03%
Shares
12 transactions
Others Institutions Holding KYMR
# of Institutions
184Shares Held
64.4MCall Options Held
50.6KPut Options Held
81.7K-
Price T Rowe Associates Inc Baltimore, MD6.65MShares$293 Million0.04% of portfolio
-
Baker Bros. Advisors LP New York, NY6MShares$264 Million3.04% of portfolio
-
Bvf Inc San Francisco, CA5.16MShares$227 Million7.77% of portfolio
-
Atlas Venture Life Science Advisors, LLC4.9MShares$216 Million28.59% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.75MShares$209 Million0.0% of portfolio
About Kymera Therapeutics, Inc.
- Ticker KYMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,705,800
- Market Cap $2.41B
- Description
- Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...